Decision: Favourable

Study Title:

A phase III, randomized, double-masked, placebo controlled, parallel-group, multicenter study of the safety and efficacy of OT-101 (Atropine 0.01%) in treating the progression of myopia in pediatric subjects

  • NREC Code:

    21-NREC-CT-007

  • Decision:

    Favourable

  • Meeting Date:

    16/06/2021

  • Study Type:

    CT application

  • Principal Investigator:

    Prof Daniel Ian Flitcroft

  • PI Institution:

    TU Dublin and Mater University Hospital

  • Sponsor:

    Ocumension (Hong Kong) Limited

Scroll to Top